Clinical Trials Browser

Phase 2 × pyrotinib × 1 year × Clear all

NCT05582499 2026-05-28

FASCINATE-N

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07610720 2026-05-28

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06563999 2026-04-21

NUMER

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Phase 2 Recruiting

Breast Neoplasms

NCT07335081 2026-03-24

ctDNA in HER2+ EBC Neoadjuvant Treatment

Phase 2 Recruiting

Breast Neoplasms

NCT07417241 2026-02-18

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07340398 2026-01-21

TAYLOR

Phase 2 Recruiting

HER2-positive Early Breast Cancer

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT07307287 2025-12-29

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05751018 2025-12-02

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07180082 2025-11-18

CORIN-PYRA

Phase 2 Recruiting

Advanced Breast Cancer

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

NCT04126525 2025-09-11

NeoATP

Phase 2 Active not recruiting

Breast Cancer Female

NCT02834936 2025-08-28

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Phase 2 Completed

Non Small Cell Lung

NCT07132242 2025-08-20

SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06973525 2025-08-05

HER2-DM-NACT

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

NCT07065435 2025-07-15

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2 Recruiting

Breast Neoplasms

NCT07053150 2025-07-08

CCGLC-018

Phase 2 Not yet recruiting

Advanced Digestive System Tumor

NCT07019337 2025-06-13

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms